# A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)

> **NCT00734097** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 314 (actual)

## Conditions studied

- Gastroesophageal Reflux Disease

## Interventions

- **DRUG:** Esomeprazole 40 mg
- **PROCEDURE:** Physical Exam
- **OTHER:** Quality of Life Questionnaires
- **PROCEDURE:** pregnancy test, if applicable

## Key facts

- **NCT ID:** NCT00734097
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 314 (ACTUAL)
- **Last updated:** 2012-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00734097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00734097, "A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00734097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*